A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at Stress

A Phase I Dosimetry, Biodistribution and Safety Study of BMS747158 in Healthy Subjects Undergoing 2-Day Rest/Stress Positron Emission Tomography

The purpose of this clinical research study is to learn the biodistribution of injection of BMS747158 at stress and assess the safety of two doses of BMS747158

Inclusion Criteria:

• age 18-40
• BMI 18-30 kg/m2
• No active or chronic illnesses
• If female: not pregnant, use of birth control or not of child-bearing potential

Exclusion Criteria:

• Significant active or chronic illness
• Any neurological disorder
• GI disease within 3 months
• Recent infection
• Major surgery within 4 weeks
• Donation of blood within 4 weeks
• Blood transfusion within 4 weeks
• Recent history drug/alcohol abuse
• Head trauma
• Significant screening ECG, EEG, lab tests, physical exam and vital signs abnormalities
• Prescription or OTC drugs within 2 weeks
• Exposure to any other investigational